Agilent Technologies Inc. (NYSE: A) today announced the availability of oligo array-based comparative genomic hybridization (Oligo aCGH) microarrays with more than a five-fold increase in density over previous offerings while maintaining the platform's superior sensitivity and reproducibility. The CGH technique is used to study DNA-copy number variations associated with a wide range of genetically related diseases including cancer and developmental syndromes such as Autism, Parkinson's and Praeder-Willi. Agilent's Oligo aCGH platform enables researchers to study these variations on a genome-wide scale at high resolution with extreme sensitivity and specificity.
